Smoker

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

Retrieved on: 
Monday, November 27, 2023
Patient, Regeneron Pharmaceuticals, Food, Smoker, Aes, Breakthrough therapy, Death, Upper respiratory tract infection, Diarrhea, FDA, Hypertension, Headache, Common, Inflammation, COVID-19, European Medicines Agency, Doctor of Philosophy, International development, Back pain, Phenotype, Safety, History, Pharmaceutical industry

TARRYTOWN, N.Y. and PARIS, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that Dupixent significantly reduced (34%) exacerbations, confirming positive results from the landmark Phase 3 BOREAS trial. The NOTUS trial also confirmed that treatment with Dupixent led to rapid and significant improvements in lung function by 12 weeks and were sustained at 52 weeks.

Key Points: 
  • “These results demonstrate the important role of type 2 inflammation in yet another chronic and debilitating disease, and the ability of Dupixent to address this inflammation.
  • Patients receiving Dupixent compared to placebo experienced:
    34% reduction in moderate or severe acute COPD exacerbations over 52 weeks (p=0.0002), the primary endpoint.
  • BOREAS results showed:
    30% reduction in moderate or severe acute COPD exacerbations over 52 weeks (p=0.0005), the primary endpoint.
  • The safety and efficacy of Dupixent in COPD are currently under clinical investigation and have not been evaluated by any regulatory authority.

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Retrieved on: 
Monday, November 27, 2023
Patient, Regeneron Pharmaceuticals, Sanofi, Food, Smoker, Death, Aes, Breakthrough therapy, Upper respiratory tract infection, Diarrhea, FDA, Hypertension, Headache, Disease, Common, Inflammation, COVID-19, European Medicines Agency, Back pain, Phenotype, Safety, History, Pharmaceutical industry

The second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.

Key Points: 
  • The second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.
  • These results were from an interim analysis and, given the overwhelming positive efficacy of the primary endpoint, will be considered the primary analysis of the trial.
  • Patients receiving Dupixent compared to placebo experienced:
    34% reduction in moderate or severe acute COPD exacerbations over 52 weeks (p=0.0002), the primary endpoint.
  • The safety and efficacy of Dupixent in COPD are currently under clinical investigation and have not been evaluated by any regulatory authority.

Global $5.16 Bn Heated Tobacco Products (HTP) Market Analysis Report, 2022 and 2023-2027 - Decrease in Consumption for Cigarettes, Rising Health Awareness and Increased Investment in R&D - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023
Tobacco, Retail, Online, HTP, Smoker, Research, Nicotine, Market, Internet, COVID-19, THP, Smoke, Advertising, Social media, Growth, Overalls, Heated tobacco product, Stick, Distribution, HTPS

Therefore, decrease in consumption of cigarettes is leading an increase in demand for HTP and hence boosting the growth of heated tobacco products (HTP) market.

Key Points: 
  • Therefore, decrease in consumption of cigarettes is leading an increase in demand for HTP and hence boosting the growth of heated tobacco products (HTP) market.
  • The global Heated tobacco products (HTP) market faces competition from other smokeless tobacco products like snus, chewing tobacco, moist snuff, and vaping products.
  • Also, stick heated tobacco products market value is the fastest growing segment of global heated tobacco products market value owing to high adoption of HTPs as a premium product and the ease of use of tobacco sticks in comparison to conventional cigarettes.
  • Within Europe, Germany held the highest share of the market, whereas UK is expected to be the fastest-growing heated tobacco products market in the forecasted period.

International vapour brand RELX Secures Top ESG Rating By S&P Global, Ranking First in Global E-vapor Industry for the Second Consecutive Year

Retrieved on: 
Thursday, December 21, 2023
Supply Chain Management, Retail, Environment, Other Retail, Tobacco, Sustainability, S&P Global, Biodiversity, Smoker, Multimedia, CSA, University, Research, City, Ethics, RMB, ESG, DNA, SCI, Disclosure, Laboratory, Social, RELX, Climate change, Social responsibility, Foreign policy, Business, MSCI, Safety, Carbon, Conduct, Renewable energy

Despite an increasingly stringent rating standard and a higher-level requirement for disclosure, RELX's ESG score rose 13% compared to last year.

Key Points: 
  • Despite an increasingly stringent rating standard and a higher-level requirement for disclosure, RELX's ESG score rose 13% compared to last year.
  • It ranked first among all global e-cigarette companies for the second consecutive year.
  • In 2022, TÜV Rheinland certified that RELX has already achieved carbon neutrality in its Beijing, Shanghai, and Shenzhen offices and laboratories.
  • In addition to its strict requirements on its operations, RELX also incorporates ESG into supply chain management.

Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
NDA, Small business, Webcast, Smoker, Annual general meeting, Herbal cigarette, U.S.–Canada Team Tournament (Go), International, Headache, ASP, FDA, Nicotine, Smoke, Pharmacokinetics, New Drug Application, Data analysis, American Society of Pharmacognosy, Cytisine, Nausea, Kidney, Insomnia, Society, JAMA, Smoking, Pharmaceutical industry, Cryptocurrency

“This has been a pivotal year for Achieve and we made significant strides to continue our progress on advancing cytisinicline throughout the third quarter,” said John Bencich, CEO of Achieve.

Key Points: 
  • “This has been a pivotal year for Achieve and we made significant strides to continue our progress on advancing cytisinicline throughout the third quarter,” said John Bencich, CEO of Achieve.
  • This trial, conducted in the United States, showcased the effectiveness and excellent tolerability of cytisinicline in adult smokers.
  • The panel highlighted the importance of industry and public partnerships in advancing new treatments, with Achieve representing an exemplary example.
  • Data analysis and final study reports for all 3 studies are expected to be completed in early 2024.

Local Research Study on COPD Flare-Ups Now Available to Residents in the Wyomissing Area

Retrieved on: 
Monday, December 11, 2023
Other Health, Research, Men, Consumer, Clinical Trials, Science, Women, Biotechnology, Seniors, FDA, Other Science, Health, Chronic obstructive pulmonary disease, COPD, Mortality, Smoker, Patient, Multimedia, Hospital, Death, Pharmaceutical industry, Nursing, Sanofi

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Wyomissing, Pa., for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in Wyomissing, Pa., for a potential treatment for reducing COPD exacerbations.
  • The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.
  • The local setting provides residents of Wyomissing, Reading, and surrounding communities the option to participate in clinical studies close to home.
  • With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

Research Study on COPD Flare-Ups Now Available to Mooresville Residents

Retrieved on: 
Monday, December 11, 2023
Other Health, Research, Men, Pharmaceutical, Consumer, Clinical Trials, Science, Cardiology, Women, Biotechnology, Seniors, Health, Chronic obstructive pulmonary disease, COPD, Mortality, Smoker, Multimedia, Hospital, Death, Pharmaceutical industry, Nursing, Sanofi

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Mooresville, N.C., for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in Mooresville, N.C., for a potential treatment for reducing COPD exacerbations.
  • The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.
  • Sever Surdulescu, the Care Access Research Investigator for this study in Mooresville.
  • With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.

Research Study on COPD Flare-Ups Now Available to Rock Hill Residents

Retrieved on: 
Monday, December 11, 2023
Biotechnology, FDA, Health, Women, Seniors, Pharmaceutical, Men, Research, Consumer, Science, Clinical Trials, Chronic obstructive pulmonary disease, COPD, Mortality, Smoker, Multimedia, Hospital, Death, Pharmaceutical industry, Nursing, Sanofi

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Rock Hill, S.C., for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in Rock Hill, S.C., for a potential treatment for reducing COPD exacerbations.
  • “Approximately one in fourteen adults in South Carolina have COPD, which is higher than the national average,” said Dr. Arun Adlakha, the Care Access Research Investigator for this study in Rock Hill.
  • Care Access opened its doors in Rock Hill in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible.
  • The community-based setting provides Rock Hill residents the option to participate in clinical studies close to home.

Research Study on COPD Flare-Ups Now Available to Greater Houston Residents

Retrieved on: 
Monday, December 11, 2023
FDA, Health, Clinical Trials, Research, Pharmaceutical, Science, Disease, Chronic obstructive pulmonary disease, COPD, Risk, Mortality, Smoker, Quality of life, Multimedia, Hospital, Death, Sanofi, Greater Houston

A new research study on chronic obstructive pulmonary disease (COPD) is now available in the Greater Houston, Texas, area for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in the Greater Houston, Texas, area for a potential treatment for reducing COPD exacerbations.
  • The AERIFY-1 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in former smokers with moderate-to-severe COPD.
  • The study is offered at Care Access locations in Houston, Conroe, Lake Jackson, and Webster.
  • The convenient settings throughout the Houston area provide local residents the option to participate in clinical studies close to home.

Research Study on COPD Flare-Ups Now Available to Greater Cincinnati Residents

Retrieved on: 
Monday, December 11, 2023
Men, Research, Other Health, Pharmaceutical, Consumer, Clinical Trials, Science, Biotechnology, Women, Seniors, FDA, Health, Other Science, Chronic obstructive pulmonary disease, COPD, Mortality, Smoker, Multimedia, Hospital, Death, Pharmaceutical industry, Nursing, Sanofi, Cincinnati metropolitan area

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Hamilton and Middletown, Ohio, for a potential treatment for reducing COPD exacerbations.

Key Points: 
  • A new research study on chronic obstructive pulmonary disease (COPD) is now available in Hamilton and Middletown, Ohio, for a potential treatment for reducing COPD exacerbations.
  • The AERIFY-1 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in former smokers with moderate-to-severe COPD.
  • Care Access opened its doors in the Greater Cincinnati area in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible.
  • With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 15 biopharmaceutical companies.